In this episode Dr. Stader and Dr. Bradley summarize and offer key insights for the following Coaches Top 5 picks, discussing buprenorphine associated precipitated withdrawal, open label placebo injections, the potential use of GLP-1 RA's in SUD, and more!
Open-Label Placebo Injection for Chronic Back Pain With Functional Neuroimaging: A Randomized Clinical Trial, Published in JAMA Network Open, September 2024
The Efficacy of GLP-1 Agonists in Treating Substance Use Disorder in Patients: A Scoping Review, Published in the Journal of Addiction Medicine, Sept/Oct 2024
Back and neck pain: in support of routine delivery of non-pharmacologic treatments as a way to improve individual and population Health, Published in Translational Research, August 2021
Management of patients at risk of harms from both continuing and discontinuing their long-term opioid therapy: A qualitative study to inform the gap in clinical practice guidelines, Published in Pain Practice, November 2024
Buprenorphine-Precipitated Withdrawal Among Hospitalized Patients Using Fentanyl, Published in JAMA Network Open, September 2024
